<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00066326</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000315521</org_study_id>
    <secondary_id>U01CA062487</secondary_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-C-2599</secondary_id>
    <secondary_id>NCI-5932</secondary_id>
    <nct_id>NCT00066326</nct_id>
  </id_info>
  <brief_title>Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia</brief_title>
  <official_title>Phase I Study Of The Combination Of 17-AAG And Imatinib Mesylate (Gleevec) In Patients With Blastic Phase, Accelerated Phase Of Chronic Mesylate Leukemia (CML) Or Patients With Chronic Phase CML Who Have Not Achieved A Cytogenetic Response With Imatinib Mesylate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes&#xD;
      necessary for cancer cell growth. Drugs used in chemotherapy such as&#xD;
      17-N-allylamino-17-demethoxygeldanamycin use different ways to stop cancer cells from&#xD;
      dividing so they stop growing or die. Combining imatinib mesylate with chemotherapy may kill&#xD;
      more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of&#xD;
      17-N-allylamino-17-demethoxygeldanamycin when given together with imatinib mesylate in&#xD;
      treating patients with chronic myelogenous leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose and dose-limiting toxicity of&#xD;
           17-N-allylamino-17-demethoxygeldanamycin (17-AAG) when administered with imatinib&#xD;
           mesylate in patients with chronic myelogenous leukemia.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, nonrandomized, multicenter, dose-escalation study of&#xD;
      17-N-allylamino-17-demethoxygeldanamycin (17-AAG).&#xD;
&#xD;
      Patients receive oral imatinib mesylate on days 1-21 and 17-AAG IV over 1 hour on days 1, 4,&#xD;
      8, and 12. Courses repeat every 21 days in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of 17-AAG until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6&#xD;
      patients experience dose-limiting toxicity. Once the MTD is determined, an additional cohort&#xD;
      of 6-10 patients receives treatment at the recommended phase II dose.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 21-42 patients will be accrued for this study within 1.5&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <primary_completion_date type="Actual">October 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tanespimycin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of chronic myelogenous leukemia, including any of the following phases:&#xD;
&#xD;
               -  Blastic phase&#xD;
&#xD;
                    -  Greater than 30% blasts in the peripheral blood or bone marrow&#xD;
&#xD;
                    -  Previously untreated disease OR refractory to or relapsed after most recent&#xD;
                       therapy&#xD;
&#xD;
               -  Accelerated phase, defined by 1 of the following:&#xD;
&#xD;
                    -  At least 15, but less than 30%, blasts in the peripheral blood or bone&#xD;
                       marrow&#xD;
&#xD;
                    -  At least 30% blasts and promyelocytes in the peripheral blood or bone marrow&#xD;
&#xD;
                    -  Greater than 20% peripheral blood basophilia&#xD;
&#xD;
               -  Chronic phase&#xD;
&#xD;
                    -  No major cytogenetic response (less than 65% Philadelphia chromosome&#xD;
                       negative) after 12 months of prior imatinib mesylate therapy&#xD;
&#xD;
          -  Philadelphia chromosome positive by routine cytogenetics&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  ALT and AST no greater than 2.5 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine less than 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No known allergy to eggs&#xD;
&#xD;
          -  Able to swallow pills&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other concurrent uncontrolled medical illness&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior stem cell transplantation&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (except hydroxyurea or anagrelide) (at&#xD;
             least 6 weeks for nitrosoureas or mitomycin)&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  No prior liver, kidney, or lung transplantation&#xD;
&#xD;
          -  More than 14 days since prior major surgery (e.g., thoracotomy or intra-abdominal&#xD;
             surgery)&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Prior imatinib mesylate administered within the past 4 weeks is allowed&#xD;
&#xD;
          -  No concurrent tacrolimus or cyclosporine as immunosuppressive agents&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No concurrent agents that alter CYP3A4 activity, including any of the following:&#xD;
&#xD;
               -  Grapefruit juice&#xD;
&#xD;
               -  Ketoconazole&#xD;
&#xD;
               -  Fluconazole&#xD;
&#xD;
               -  Itraconazole&#xD;
&#xD;
               -  Erythromycin&#xD;
&#xD;
               -  Clarithromycin&#xD;
&#xD;
               -  Cimetidine&#xD;
&#xD;
               -  Terfenadine&#xD;
&#xD;
               -  Astemizole&#xD;
&#xD;
               -  HIV protease inhibitors (e.g., indinavir and nelfinavir)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles A. Schiffer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>August 6, 2003</study_first_submitted>
  <study_first_submitted_qc>August 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2003</study_first_posted>
  <last_update_submitted>April 3, 2013</last_update_submitted>
  <last_update_submitted_qc>April 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

